Navigation Links
Aida Pharmaceuticals, Inc. Announces Update on Progress of Rh-Apo2L Testing
Date:4/28/2008

SANTA MONICA, Calif., April 28 /PRNewswire-FirstCall/ -- Aida Pharmaceuticals, Inc. (OTC Bulletin Board: AIDA) today announced that the Company is compiling data for its Phase 2 testing results of Rh-Apo2L and expects to announce the findings within the next month. The Company previously announced that the target cancers for the drug have been determined and initial results are extremely positive. The cancer targets that the Company has chosen are ailments which Rh-Apo2L has shown the most efficacy and which have the most market potential. The Company previously announced that Rh-Apo2L testing results have shown strong efficacy in treating non-small cell lung cancer, non-Hodgkins lymphoma, stomach cancer, pancreatic cancer and kidney cancer.

The Company intends to immediately file for Phase 3 clinical testing with the People's Republic of China's State Food and Drug Administration after the announcement of the findings from Phase 2 testing. The Company anticipates that the Chinese government will then allow for the commencement of Phase 3 testing within two to three months after the Phase 2 results are published. Phase 3 testing will entail large-volume tests on over 300 patients and is the last step before it may be commercially sold in the People's Republic of China.

About Rh-Apo2L- The Anti-Cancer Drug

Rh-Apo2L is a pioneering biotechnology gene therapy drug used to treat certain forms of cancer. This biopharmaceutical drug has gained the attention of researchers and clinical professionals throughout the People's Republic of China who are observing the drug for potential replacement of surgery and radiation therapy for cancer. Potentially, over 8 million lives can be saved each year in the People's Republic of China by this drug.

About Aida Pharmaceuticals

Aida Pharmaceuticals is a product-focused pharmaceuticals company engaged in the formulation, clinical testing, registration, manufacture, sales and marketing of advanc
'/>"/>

SOURCE Aida Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Aida Pharmaceuticals, Inc. Announces Completion of Research Institute Acquisition
2. GlaxoSmithKline to Acquire Sirtris Pharmaceuticals, a World Leader in Sirtuin Research and Development
3. Pacira Pharmaceuticals, Inc. Expands Development Collaborations for DepoFoam(R)
4. Laureate Pharma Announces Manufacturing Agreement With Alopexx Pharmaceuticals, LLC
5. Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights
6. Aida Pharmaceuticals, Inc. Acquires High-Level Research Institute in the Peoples Republic of China
7. Jazz Pharmaceuticals, Inc. Announces Expansion of Senior Debt
8. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
9. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
10. Acura Pharmaceuticals, Inc. Reports 2007 4th Quarter and Annual Financial Results; Sets 2008 Expectations
11. Investor Alert from Cauley Bowman Carney & Williams, PLLC: Update on Proposed Acquisition of CollaGenex Pharmaceuticals, Inc. - CGPI
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... device," Nobel laureate Herbert Kroemer famously observed, referring ... the junctures where layers of different materials meet. ... between layers of metal oxides are becoming increasingly ... spintronics, high-temperature superconductors, ferroelectrics and multiferroics. Realizing the ...
(Date:1/15/2014)... Jan. 15, 2014   Niagara Thermal Products is ... Buffalo BioBlower Technologies LLC ("B3") as the critical thermal ... award from the Army Corps of Engineers.  B3 has ... all biological contaminants and destroys VOCs and other chemical ...
(Date:1/15/2014)... SAN JOSE, California , January 15, 2014 ... for cancer, today announced the appointment of Thomas C Reynolds ... over 20 years, development experience gained in the biotechnology industry, ... "I am delighted to welcome Tom at this transformative ...
(Date:1/15/2014)... A study has been launched to test whether ... could help to tackle the problem of obesity.  This unique ... surgery based in Stowmarket) and academics at University Campus Suffolk ... technology, which is inspired by equipment used to collect data ...
Breaking Biology Technology:A deeper look at interfaces 2Niagara Thermal Products LLC Selected as Critical Supplier for Buffalo BioBlower Air Purification Systems 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4
... CITY, QC, Sept. 10 /PRNewswire-FirstCall/ - Mr. Pierre,Fitzgibbon, ... ("Atrium" or the "Company", TSX: ATB) today announced ... follow the decision by Mr.,Richard Bordeleau, President of ... in order to pursue news challenges. However, Mr. ...
... MichBio, the association for,Michigan,s life sciences industry, announced ... in Lansing. Guided tours will be available to ... 1 of the Expo, October 16. Attendees must register ... credentials and maps to the,locations. Visitors will transport themselves ...
... the Journal Nature Medicine, CLEVELAND, Sept. 10 ... normal cholesterol levels, yet seemingly,misses striking others who smoke, ... help explain why one person suffers a heart attack,and ... Research Institute have,discovered a mechanism that contributes to the ...
Cached Biology Technology:Atrium Innovations Announces Management Changes 2MichBio Announces Expo Tours; Extends Deadline for Innovator Showcase Applications 2Cleveland Clinic-Led Research Uncovers New Mechanism That Heightens Risk of Heart Disease 2Cleveland Clinic-Led Research Uncovers New Mechanism That Heightens Risk of Heart Disease 3
(Date:7/9/2014)... neuronal function and increase the survival rate of ... team, School of Pharmaceutical Sciences, Southwest University, China ... were administered with low dose of levothyroxine for ... rats exhibited an obvious improvement in cognitive and ... 93%. The underlying mechanism was demonstrated that levothyroxine ...
(Date:7/9/2014)... less fit in terms of cardiorespiratory capacity, strength ... southern adolescents are more obese and present higher ... from the centre-north of Europe. , These are ... study conducted by scientists from the University of ... 25 other European research groups. The study compared ...
(Date:7/9/2014)... Jena (Germany) They are amongst the most numerous inhabitants ... Emiliania huxleyi . Not visible to the naked eye, ... square kilometer sized patches, they are even visible on ... is responsible for approximately half of the global ... Friedrich Schiller University Jena (Germany). In the process the ...
Breaking Biology News(10 mins):Adolescents from southern Europe are less fit and more obese than central-northern European peers 2Short circuit in the food web 2
... gas could be produced from rotting organic matter like food ... pushing governments to use that ancient knowledge to turn household ... energy. Our environment would be the winner since less waste ... However, while the scientific theory is simple, treating the flow ...
... tricks and survival strategies of viruses to effectively ... virtual institute VISTRIE that received its funding commitment ... Immune Evasion", is a joint program grant with ... Association of German Research Centres. Coordinated by the ...
... ,As our bodies first form, developing cells are a lot ... addresses pinned to their shirts. The notes identify one as ... as a neuron. And that,s what they each grow up to ... original marching orders caused by aging, disease and other stressors like ...
Cached Biology News:Time to make more out of waste 2Time to make more out of waste 3Virtual Institute investigates virus infections 2Mutations can spur dangerous identity crisis in cells 2
Human HVEM/TNFRSF14 Allophycocyanin MAb (Clone 94801)...
Enodgenous alkaline phosphotase inhibitor. Levamisole solution is supplied in concentrated form (20x). The final concentration of levamisole in the substrate solution will be 1 mM....
X-gal,1g...
...
Biology Products: